The Penicillins and Streptomycins dosage market in Malaysia exhibited a robust growth trajectory from 2012 to 2021, increasing from $22.254 million to $56.186 million. This growth was characterized by a steady year-on-year rise, with notable surges in 2018 and 2020, contributing to compounded annual growth rates (CAGR) of up to 16.96% during some periods. However, 2022 experienced a slight decline, registering a -5.09% year-on-year variation, leading to a mixed CAGR of 8.45% over the last 5 years. As of 2023, the market remained a significant segment within the pharmaceutical industry.
Looking ahead, several future trends should be monitored:
- The impact of emerging antibiotic resistance on market demand.
- Potential market shifts due to healthcare policy changes and pharmaceutical innovations.
- Increased investment in R&D for novel antibiotics and formulations.
- Economic factors influencing healthcare expenditure in Malaysia.
How does Malaysia rank in Penicillins and Streptomycins in Dosage Market Size Value?
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | View data |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
| 15 | 15 Peru | 80,808,000 | 2023 | +1.93% | +2.15% | View data |
| 16 | 16 Chile | 68,962,000 | 2023 | +0.58% | +0.71% | View data |
| 17 | 17 Malaysia | 62,268,000 | 2023 | +7.35% | +7.89% | |
| 18 | 18 Czech Republic | 60,391,000 | 2023 | -3.18% | -4.46% | View data |
| 19 | 19 New Zealand | 59,707,000 | 2023 | -1.18% | -1.53% | View data |
